Journal article
Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer
DJ Jonker, CS Karapetis, C Harbison, CJ O'Callaghan, D Tu, RJ Simes, DP Malone, C Langer, N Tebbutt, TJ Price, J Shapiro, LL Siu, RPW Wong, G Bjarnason, MJ Moore, JR Zalcberg, S Khambata-Ford
British Journal of Cancer | NATURE PUBLISHING GROUP | Published : 2014
DOI: 10.1038/bjc.2013.753
Abstract
Background:Anti-EGFR antibody, cetuximab, improves overall survival (OS) in K-ras wild-type chemotherapy-refractory colorectal cancer. Epidermal growth factor receptor ligand epiregulin (EREG) gene expression may further predict cetuximab benefit.Methods:Tumour samples from a phase III clinical trial of cetuximab plus best supportive care (BSC) vs BSC alone (CO.17) were analysed for EREG mRNA gene expression. Predictive effects of high vs low EREG on OS and progression-free survival (PFS) were examined for treatment-biomarker interaction.Results:Both EREG and K-ras status were ascertained in 385 (193 cetuximab, 192 BSC) tumour samples. Within the high EREG and K-ras wild-type status ('co-bio..
View full abstractGrants
Funding Acknowledgements
This work was supported by the Canadian Cancer Society through the NCIC Clinical Trials Group, ImClone Systems and Bristol-Myers Squibb.